Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study
Oka T, Kimura T, Suzumura T, Yoshimoto N, Nakai T, Yamamoto N, Matsuura K, Mitsuoka S, Yoshimura N, Kudoh S, Hirata K
BMC pharmacology & toxicology · 31 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Estudio de cohortes (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2014-12-01 · BMC Pharmacol Toxicol · vol. 15 · número 1 · pág. 70
- Editorial
- BioMed Central
- Citado
- 47 citas · más que el 89% de estudios similares · 2.6× el promedio de su campo
- Referencias
- 25 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Chemotherapy-induced organ toxicity mitigation · Magnesium in Health and Disease · Potassium and Related Disorders
- Palabras clave
- Toxicity, Cisplatin, Renal function, Creatinine, Urology, Medicine, Chemotherapy, Diuresis, Pharmacology, Internal medicine
- MeSH
- humans, lung neoplasms, kidney diseases, cisplatin, magnesium, water, creatinine, serum albumin, hemoglobins, antineoplastic agents, antineoplastic combined chemotherapy protocols, rehydration solutions, aged, middle aged, female, male
11 autores
- Takako Oka🇯🇵Osaka City University
- Tatsuo Kimura🇯🇵 · autor de correspondenciaOsaka City University; Osaka City University Hospital
- Tomohiro Suzumura🇯🇵Izumi City General Hospital
- Naoki Yoshimoto🇯🇵Osaka City University
- Toshiyuki Nakai🇯🇵Osaka City University
- Norio Yamamoto🇯🇵Osaka City University
- Kuniomi Matsuura🇯🇵Osaka City University
- Shigeki Mitsuoka🇯🇵Osaka City University
- Naruo Yoshimura🇯🇵Osaka City University
- Shinzoh Kudoh🇯🇵Osaka City University
- Kazuto Hirata🇯🇵Osaka City University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Renal toxicity is a clinical problem that affects 28-42% of patients undergoing treatment with cisplatin. Renal toxicity can be minimized by high volume hydration with mannitol diuresis. Recent reports have shown that cisplatin induces depletion of Mg and that Mg supplementation can reduce renal toxicity. We hypothesized that Mg infusion combined with low volume hydration may not be sufficient to overcome cisplatin-induced renal toxicity.
Methods
In total, 85 patients with lung cancer receiving their first cycle of cisplatin-based chemotherapy at the Osaka City University Hospital were classified into three groups: those administered high volume hydration without Mg infusion (high-volume Mg-), high volume hydration with Mg infusion (high-volume Mg+), and with low volume hydration with Mg infusion (low-volume Mg+). Serum creatinine (sCr) and creatinine clearance (CrCl) were examined before and after treatment with cisplatin. Multivariable analysis was carried out to identify the most important contributing factors.
Results
There were no significant differences in pre-treatment sCr levels or CrCl between groups. In the high-volume Mg- group, post-treatment sCr significantly increased compared with pre-treatment levels, while post-CrCl significantly decreased compared with pre-treatment CrCl (p < 0.001 and p < 0.001, respectively). In the high-volume Mg+ group, there was no significant difference between pre- and post-treatment levels of sCr, or between pre- and post-treatment CrCl (p = 0.118 and p = 0.254, respectively). In the low-volume Mg+ group, there was a trend towards increased sCr levels and decreased CrCl after treatment (p = 0.068 and p = 0.055, respectively). Multivariate analysis revealed that the absence of Mg infusion and low-volume hydration were both independent factors for decreased CrCl (p < 0.001 and p = 0.001, respectively).
Conclusions
High-volume hydration and Mg infusion reduces the renal toxicity induced by cisplatin. A low-volume Mg+ regimen may be considered for patients with adequate renal function.
Trial registration
Observational Study UMIN000013950; Registered 13 May 2014.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.